Stream
Stories
-
Eli Lilly registers Phase 3 study of EloraTZP in obesity
The study, NCT07881432 (AMPLIFY-1), was first posted on ClinicalTrials.gov on October 19, 2026. It plans to enroll 2115 participants, start in December 2026, and reach primary completion in October 2029.
-
Beeline registers Phase 2/3 study of afimetoran in cutaneous lupus erythematosus
The study, led by Beeline Medicines Corporation, plans to enroll 390 participants and begin in October 2026. It evaluates afimetoran versus placebo over 24 weeks, with a total treatment period of 52 weeks, and aims to assess changes in the CLASI-A skin activity score.
-
R-Pharm registers Phase 3 study of Goflikicept in pediatric FMF
The study plans to enroll 18 participants and plans to begin in December 2026, with primary completion projected for May 2029. It aims to evaluate the pharmacokinetics, efficacy, and safety of goflikicept in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever.
-
Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes
The study plans to enroll 1000 participants, start in November 2026, and reach primary completion in October 2029. It aims to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide in adults with obesity or overweight and type 2 diabetes.
-
Protagonist posts results of Phase 3 rusfertide study in polycythemia vera
The study enrolled 293 participants and was completed with primary data collected by February 21, 2025. Results were first posted on ClinicalTrials.gov on October 19, 2026.
-
Johnson & Johnson reports one-year FUZION results for TREMFYA in Crohn's disease
The company said TREMFYA maintained combined fistula remission through 48 weeks in adults with Crohn's disease and perianal fistula, with 35% remission at Week 48 in the 100 mg q8w group. More than 90% of all randomized patients completed treatment through Week 48, and safety findings were consistent with the established safety profile.
-
Lilly's Omvoh meets primary endpoint of clinical remission in pediatric ulcerative colitis
In the single-arm, open-label Phase 3 SHINE-2 study, 81% of 63 pediatric patients achieved clinical response at Week 12 and 50% of responders were in clinical remission at Week 52, meeting the study's primary endpoint. The safety profile through Week 52 was consistent with that seen in adults, with no new safety signals reported.
-
AbbVie announces data to be presented at 2026 ESMO Congress
AbbVie today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. The presentations cover investigational assets such as Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, EmrelisTM and Elahere.
-
CMS, SBA, Take Command discuss CHOICE Arrangements for Ohio small businesses
The Centers for Medicare & Medicaid Services, the Small Business Administration, and Take Command met to explore CHOICE Arrangements, a tax-advantaged contribution model that lets Ohio employers replace traditional group plans with individual coverage options. CMS Administrator Dr. Mehmet Oz said CHOICE Arrangements help Ohio employers better manage healthcare costs while empowering workers to choose coverage that meets their individual needs.
-
AstraZeneca registers Phase 3 trial of durvalumab and FLOT in Chinese gastric cancer patients
The study, titled MATTERHORN-CN, plans to enroll 140 participants and plans to start on November 30, 2026. It compares neoadjuvant-adjuvant durvalumab plus FLOT chemotherapy to placebo plus FLOT in resectable gastric and gastroesophageal junction cancer.
-
Eli Lilly posts results of Phase 3 lebrikizumab trial in atopic dermatitis
Results for the Phase 3 trial of lebrikizumab with or without topical corticosteroid treatment in participants with moderate-to-severe atopic dermatitis were first posted on ClinicalTrials.gov on October 16, 2026. The completed study enrolled 301 participants and began on April 24, 2024.
-
Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study
The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.